Cypherpunk Technologies INC. (CYPH) — SEC Filings

Overview

Cypherpunk Technologies INC. (CYPH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 144 filed on Mar 27, 2026: On March 27, 2026, Cypherpunk Technologies Inc. filed a Form 144, indicating a proposed sale of securities. The filing was made by Christopher Mirabelli, who is associated with the company. The specific number of shares and dollar amount are not detailed in this excerpt.

Sentiment Summary

Across 42 filings, the sentiment breakdown is: 5 bearish, 36 neutral, 1 mixed. The dominant filing sentiment for Cypherpunk Technologies INC. is neutral.

Filing Type Overview

Cypherpunk Technologies INC. (CYPH) has filed 1 144, 24 8-K, 2 DEFA14A, 3 DEF 14A, 5 10-Q, 2 10-K, 3 SC 13G, 1 SC 13D/A, 1 SC 13G/A with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (42)

• Cypherpunk Technologies Files Form 144 for Security Sale — 144 · Mar 27, 2026 Risk: medium
  On March 27, 2026, Cypherpunk Technologies Inc. filed a Form 144, indicating a proposed sale of securities. The filing was made by Christopher Mirabelli, who is
• Cypherpunk Technologies Inc. Files 8-K — 8-K · Dec 30, 2025 Risk: low
  Cypherpunk Technologies Inc. filed an 8-K on December 30, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure
• 8-K Filing — 8-K · Dec 16, 2025
• Cypherpunk Technologies Inc. Enters Material Definitive Agreement — 8-K · Nov 20, 2025 Risk: medium
  On November 19, 2025, Cypherpunk Technologies Inc. entered into a material definitive agreement. The company, formerly known as Leap Therapeutics, Inc. and Dekk
• Cypherpunk Technologies Inc. Files Proxy Statement — DEFA14A · Nov 19, 2025 Risk: low
  Cypherpunk Technologies Inc. (formerly Leap Therapeutics, Inc. and Dekkun Corp) filed a Definitive Proxy Statement (DEFA14A) on November 19, 2025. The company,
• 8-K Filing — 8-K · Nov 18, 2025
• Leap Therapeutics Files 8-K with Key Corporate Updates — 8-K · Nov 12, 2025 Risk: medium
  On November 11, 2025, Leap Therapeutics, Inc. filed an 8-K report detailing several key events. These include entering into a material definitive agreement, rep
• Leap Therapeutics Seeks Shareholder Nod for Reverse Split, Digital Asset Strategy — DEF 14A · Nov 3, 2025 Risk: high
  LEAP THERAPEUTICS, INC. (CYPH) is holding a Special Meeting on December 15, 2025, to approve several critical proposals following a private placement transactio
• Leap Therapeutics Files 8-K — 8-K · Oct 20, 2025 Risk: low
  On October 20, 2025, Leap Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific
• Leap Therapeutics Files 8-K: Material Agreement, Equity Sales — 8-K · Oct 9, 2025 Risk: medium
  On October 6, 2025, Leap Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities a
• Leap Therapeutics Files 8-K Report — 8-K · Oct 6, 2025 Risk: low
  On October 6, 2025, Leap Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific
• Leap Therapeutics Faces Delisting Concerns — 8-K · Sep 11, 2025 Risk: high
  Leap Therapeutics, Inc. filed an 8-K on September 11, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earl
• Leap Therapeutics Files 8-K on Financials — 8-K · Aug 14, 2025 Risk: low
  On August 14, 2025, Leap Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
• Leap Therapeutics' Cash Dwindles Amidst Restructuring, Going Concern Warning — 10-Q · Aug 14, 2025 Risk: high
  LEAP THERAPEUTICS, INC. (CYPH) reported a net loss of $16.643 million for the three months ended June 30, 2025, an improvement from the $20.128 million net loss
• Leap Therapeutics Files 8-K on Executive Changes & Corporate Actions — 8-K · Jun 23, 2025 Risk: medium
  On June 23, 2025, Leap Therapeutics, Inc. filed an 8-K report detailing several key events. The company reported on cost associated with exit or disposal activi
• Leap Therapeutics Files 8-K on Financials — 8-K · May 13, 2025 Risk: low
  Leap Therapeutics, Inc. filed an 8-K on May 13, 2025, reporting on its Results of Operations and Financial Condition, and filing Financial Statements and Exhibi
• Leap Therapeutics Q1 2025 Financial Update — 10-Q · May 13, 2025 Risk: medium
  Leap Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $41.4 million and total liabilities of $3.8 mi
• Leap Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 28, 2025 Risk: low
  Leap Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 28, 2025, for its annual meeting of stockholders scheduled for June 18, 2025. Th
• Leap Therapeutics Files 8-K on Financials and Operations — 8-K · Mar 26, 2025 Risk: low
  On March 26, 2025, Leap Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along
• Leap Therapeutics Files 2024 10-K — 10-K · Mar 26, 2025 Risk: medium
  Leap Therapeutics, Inc. filed its 2024 10-K on March 26, 2025, reporting financial results for the fiscal year ending December 31, 2024. The company, incorporat
• Leap Therapeutics Faces Delisting Concerns — 8-K · Mar 17, 2025 Risk: high
  Leap Therapeutics, Inc. filed an 8-K on March 17, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest
• Leap Therapeutics Files 8-K Report — 8-K · Jan 28, 2025 Risk: low
  On January 28, 2025, Leap Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific
• SC 13G Filing — SC 13G · Nov 14, 2024
• Leap Therapeutics Files 8-K on Financials — 8-K · Nov 13, 2024 Risk: low
  On November 13, 2024, Leap Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as
• Leap Therapeutics Q3 2024 Update: Assets & Liabilities Detailed — 10-Q · Nov 13, 2024 Risk: medium
  Leap Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $25.6 million and total liabilities of $38
• BeiGene Files SC 13D/A Amendment for Leap Therapeutics — SC 13D/A · Oct 31, 2024 Risk: medium
  BeiGene, Ltd. filed an amendment (Amendment No. 2) to its Schedule 13D on October 31, 2024, regarding its holdings in Leap Therapeutics, Inc. The filing indicat
• Leap Therapeutics Files 8-K Report — 8-K · Sep 30, 2024 Risk: low
  On September 30, 2024, Leap Therapeutics, Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware, is ba
• Leap Therapeutics Files 8-K on Financials — 8-K · Aug 12, 2024 Risk: low
  On August 12, 2024, Leap Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The company, incorporated in Delaware with its p
• Leap Therapeutics Reports Q2 2024 Results — 10-Q · Aug 12, 2024 Risk: high
  Leap Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $25.57 million and total liabilities of $4.20 m
• Leap Therapeutics Files 8-K on Security Holder Vote — 8-K · Jul 8, 2024 Risk: low
  On July 2, 2024, Leap Therapeutics, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing does not specify
• Leap Therapeutics Files Proxy Statement Supplement — DEFA14A · May 16, 2024 Risk: low
  Leap Therapeutics, Inc. (LEAP) filed a DEFA14A, which is a supplement to its proxy statement. This filing provides additional materials related to the company's
• Leap Therapeutics Files 8-K with Financial Updates — 8-K · May 13, 2024 Risk: low
  On May 13, 2024, Leap Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibi
• LEAP THERAPEUTICS, INC. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: low
  LEAP THERAPEUTICS, INC. (CYPH) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. LEAP THERAPEUTICS, INC. filed a 10-Q for the period ending March 31
• Leap Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 29, 2024 Risk: low
  LEAP THERAPEUTICS, INC. (CYPH) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Leap Therapeutics, Inc. will hold its 2024 Annual Meeting of St
• SC 13G Filing — SC 13G · Apr 25, 2024
• SC 13G Filing — SC 13G · Apr 19, 2024
• Leap Therapeutics Files 8-K: Material Agreement & Equity Sales — 8-K · Apr 11, 2024 Risk: medium
  On April 10, 2024, Leap Therapeutics, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The compan
• Leap Therapeutics Files 8-K on Financials — 8-K · Mar 18, 2024 Risk: low
  On March 18, 2024, Leap Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along
• LEAP THERAPEUTICS, INC. Files 2023 Annual Report on Form 10-K — 10-K · Mar 18, 2024 Risk: high
  LEAP THERAPEUTICS, INC. (CYPH) filed a Annual Report (10-K) with the SEC on March 18, 2024. Leap Therapeutics reported total assets of $25,565,414 as of Decembe
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Leap Therapeutics Files 8-K for 'Other Events' on Jan 23, 2024 — 8-K · Jan 23, 2024
  Leap Therapeutics, Inc. filed an 8-K on January 23, 2024, to report an "Other Event" and "Financial Statements and Exhibits." This filing indicates that the com
• Leap Therapeutics Confirms Nasdaq Listing & Admin Details — 8-K · Jan 16, 2024
  Leap Therapeutics, Inc. filed an 8-K on January 16, 2024, to update its registration information, specifically noting its Common Stock, par value $0.001, is tra

Risk Profile

Risk Assessment: Of CYPH's 34 recent filings, 6 were flagged as high-risk, 10 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Cypherpunk Technologies INC.'s most recent 10-Q filing (Aug 14, 2025):

• Net Income: -$16.64M
• EPS: -$0.40
• Cash Position: $18.13M
• Total Assets: $20.04M

Key Executives

• Christopher Mirabelli
• 0001262326
• Christopher K. Mirabelli
• Douglas E. Onsi

Industry Context

Leap Therapeutics operates in the highly competitive biotechnology sector, focusing on developing novel oncology therapeutics. The industry is characterized by long development cycles, significant R&D investment, and high failure rates. Success often hinges on the ability to navigate complex clinical trials and secure regulatory approvals, as well as manage substantial capital requirements.

Top Tags

sec-filing (7) · corporate-governance (5) · financial-reporting (5) · financials (5) · 8-K (4) · material-agreement (4) · Biotechnology (4) · 10-Q (4) · proxy-statement (3) · 8-k (3)

Key Numbers

• Aggregate gross proceeds: $58,888,888 — From the Financing Transaction before deducting fees and transaction costs
• Shares of common stock sold: 15,212,311 — In the Financing Transaction
• Pre-funded warrants shares: 80,768,504 — To purchase common stock in the Financing Transaction
• Common warrants shares: 71,985,605 — To purchase common stock at an exercise price of $0.5335 per share
• Current authorized shares: 250,000,000 — Proposed to increase to 500,000,000
• Proposed authorized shares: 500,000,000 — Increase from 250,000,000
• Minimum reverse stock split ratio: 1:5 — To regain Nasdaq compliance
• Maximum reverse stock split ratio: 1:20 — To regain Nasdaq compliance
• Nasdaq Listing Rule 5635 threshold: 19.99% — Proposed issuance of shares upon warrant exercise exceeds this threshold
• Shares of Common Stock outstanding: 56,651,840 — As of the Record Date, October 24, 2025
• SEC File Number: 001-37990 — Identifies the company's filing with the SEC
• EIN: 27-4412575 — Employer Identification Number for tax purposes
• Cash and Cash Equivalents: $18.13M — Decreased from $47.249M at Dec 31, 2024, to $18.130M at June 30, 2025, a 61.6% drop.
• Accumulated Deficit: $499.45M — Increased from $467.371M at Dec 31, 2024, to $499.449M at June 30, 2025.
• Net Loss (Q2 2025): $16.64M — Improved from $20.128M in Q2 2024, but still a significant loss.

Related Companies

LEAP · LPTX

Frequently Asked Questions